They Read the Reports - Let Two Thousand Bleed Quietly

They Read the Reports - Let Two Thousand Bleed Quietly They kept vials of clotting factor concentrates in home refrigerators like insulin, but internal ministry files show officials read warnings about contaminated blood and chose not to act. Around two thousand of Japan's roughly 4,500 haemophiliacs contracted HIV in the 1980s-so who decided to keep the heat‑treated, safer product off the market, and why? In this episode, we lay out the sequence recorded in ministry and corporate documents: the arrival of a heat‑treated product from Baxter Travenol, a one‑week reversal of a committee recommendation to ban untreated imports, and the ties between regulators and industry that shaped the decision. What did the internal reports say, who read them, and how did those choices translate into infections? Person: Green Cross Corporation executives and Ministry bureaucrats Topic: HIV infections among haemophiliacs linked to blood products Date: 1979-1986 (first known infection 1979; key events 1981-1983) Location: Japan Event: Withdrawal of committee recommendation within one week to ban untreated imports - Approximately 2,000 of Japan's ~4,500 haemophiliacs contracted HIV during the 1980s. - Baxter Travenol notified Japan's Ministry in 1983 that it had an FDA‑licensed heat‑treated clotting factor. - The ministry committee recommended banning untreated imports and emergency licensing of the heat‑treated product, then formally withdrew that recommendation within one week. - At least nine former Ministry bureaucrats took executive roles in Japan's blood products companies (amakudari pattern). - Japan imported tens of millions of units of clotting factor concentrate and millions of litres of plasma in the late 1970s-early 1980s. To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com. © 2026 OBOMEDIA. All rights reserved. This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: [email protected].